Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies
Julien Edeline(Inserm), Tomoki Ebata(Nagoya University), J. Watelet(Centre Hospitalier Régional et Universitaire de Nancy), David Malka(Inserm), Katsuhiko Uesaka(Shizuoka Cancer Center), Yoshiyasu Ambo(Hokkaido University of Science), Jean‐Paul Joly, Masayuki Ohtsuka(Chiba University), Jean–Marc Phelip(Centre Hospitalier Universitaire de Saint-Étienne), Pascal Hammel(Hôpital Paul-Brousse), M. Benabdelghani(Levi Strauss (United States)), Masahiko Ando(Nagoya University Hospital), Masaru Konishi(Shizuoka Cancer Center), Aurélie Bertaut(Institut de Cancérologie de Bourgogne), Laure Monard(UniCancer Group), Satoshi Hirano(Hokkaido University of Science), Yuji Kaneoka(Ogaki Municipal Hospital), Masakazu Yamamoto(Tokyo Women's Medical University), Masato Nagino(Nagoya University), Christophe Louvet(Institute Mutualiste Montsouris)
Cited by 38
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k